Literature DB >> 18382639

The use of antiviral drugs for influenza: recommended guidelines for practitioners.

Upton D Allen1, Fred Y Aoki, H Grant Stiver.   

Abstract

The present document outlines current guidelines and supporting literature relating to the use of antiviral drugs for chemoprophylaxis and influenza illness therapy in paediatric and adult settings. The focus is on the management of influenza in interpandemic periods. Where appropriate, the areas in need of additional research are identified. It will be necessary to update aspects of these guidelines as new information emerges. The recommendations that follow represent the results of a joint effort supported by the Canadian Paediatric Society and the Association of Medical Microbiology and Infectious Disease Canada.

Keywords:  Antiviral therapy; Influenza; M2 inhibitors; Neuraminidase inhibitors

Year:  2006        PMID: 18382639      PMCID: PMC2095091          DOI: 10.1155/2006/165940

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  50 in total

1.  Prevention of otitis media in children with live attenuated influenza vaccine given intranasally.

Authors:  R B Belshe; W C Gruber
Journal:  Pediatr Infect Dis J       Date:  2000-05       Impact factor: 2.129

2.  Oseltamivir phosphate in infants under 1 year of age with influenza infection.

Authors:  Daisuke Tamura; Takuma Miura; Yutaka Kikuchi
Journal:  Pediatr Int       Date:  2005-08       Impact factor: 1.524

3.  Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2).

Authors:  E E Mast; M W Harmon; S Gravenstein; S P Wu; N H Arden; R Circo; G Tyszka; A P Kendal; J P Davis
Journal:  Am J Epidemiol       Date:  1991-11-01       Impact factor: 4.897

4.  Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-12-12       Impact factor: 79.321

5.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

Authors:  F G Hayden; A D Osterhaus; J J Treanor; D M Fleming; F Y Aoki; K G Nicholson; A M Bohnen; H M Hirst; O Keene; K Wightman
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

6.  Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.

Authors:  A S Monto; D M Fleming; D Henry; R de Groot; M Makela; T Klein; M Elliott; O N Keene; C Y Man
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

7.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Authors:  J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

8.  The predictive value of influenza symptomatology in elderly people.

Authors:  T M Govaert; G J Dinant; K Aretz; J A Knottnerus
Journal:  Fam Pract       Date:  1998-02       Impact factor: 2.267

9.  Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.

Authors:  Jonathan A McCullers
Journal:  J Infect Dis       Date:  2004-06-30       Impact factor: 5.226

10.  Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir.

Authors:  L M Cass; K A Gunawardena; M M Macmahon; A Bye
Journal:  Respir Med       Date:  2000-02       Impact factor: 3.415

View more
  10 in total

1.  Release of the statement on influenza for the 2007 2008 season from the National Advisory Committee on Immunization.

Authors:  Joanne M Langley
Journal:  CMAJ       Date:  2007-10-23       Impact factor: 8.262

2.  A near-fatal infection with oseltamivir-resistant seasonal influenza A in a previously healthy child: Case report.

Authors:  Jesse Papenburg; Christos Karatzios; Yan Li; Nathalie Bastien; Makeda Semret; Dorothy Moore
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 3.  Amantadine and rimantadine for influenza A in children and the elderly.

Authors:  Márcia G Alves Galvão; Marilene Augusta Rocha Crispino Santos; Antonio J L Alves da Cunha
Journal:  Cochrane Database Syst Rev       Date:  2014-11-21

4.  Pandemic preparedness in Hawaii: a multicenter verification of real-time RT-PCR for the direct detection of influenza virus types A and B.

Authors:  A Christian Whelen; Matthew J Bankowski; Glenn Furuya; Stacey Honda; Robert Ueki; Amelia Chan; Karen Higa; Diane Kumashiro; Nathaniel Moore; Roland Lee; Terrie Koyamatsu; Paul V Effler
Journal:  Public Health Rep       Date:  2010 May-Jun       Impact factor: 2.792

Review 5.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: Influenza life-cycle and currently available drugs.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-09

Review 6.  Substantial effect of phytochemical constituents against the pandemic disease influenza-a review.

Authors:  A Brindha Devi; R Sarala
Journal:  Futur J Pharm Sci       Date:  2021-06-12

Review 7.  Insight into alternative approaches for control of avian influenza in poultry, with emphasis on highly pathogenic H5N1.

Authors:  E M Abdelwhab; Hafez M Hafez
Journal:  Viruses       Date:  2012-11-19       Impact factor: 5.048

Review 8.  Diagnostic testing or empirical therapy for patients hospitalized with suspected influenza: what to do?

Authors:  Allison J McGeer
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

9.  Development and evaluation of a rapid nucleic acid amplification method to detect influenza A and B viruses in human respiratory specimens.

Authors:  Sonja Elf; Pauliina Auvinen; Lisa Jahn; Karoliina Liikonen; Solveig Sjöblom; Päivi Saavalainen; Minna Mäki; Kevin E Eboigbodin
Journal:  Diagn Microbiol Infect Dis       Date:  2018-04-18       Impact factor: 2.803

Review 10.  Interleukin-17-A multifaceted cytokine in viral infections.

Authors:  Utkarsha Sahu; Debasis Biswas; Vijay Kumar Prajapati; Anirudh K Singh; Mukesh Samant; Prashant Khare
Journal:  J Cell Physiol       Date:  2021-06-16       Impact factor: 6.513

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.